<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01753102</url>
  </required_header>
  <id_info>
    <org_study_id>CLR_10_19</org_study_id>
    <secondary_id>CTRI/2012/09/002983</secondary_id>
    <nct_id>NCT01753102</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Of Spil's Estradiol Vaginal Tablet</brief_title>
  <official_title>EFFICACY AND SAFETY OF SPIL'S ESTRADIOL VAGINAL TABLET, 10 MCG ESTRADIOL IN SUBJECTS WITH VULVAR AND VAGINAL ATROPHY: A RANDOMIZED, OBSERVER BLIND, PARALLEL GROUPS, ACTIVE AND PLACEBO CONTROLLED, CLINICAL ENDPOINT BIOEQUIVALENCE STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharmaceutical Industries Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharmaceutical Industries Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Estradiol vaginal tablet is a tablet which hydrates upon contact with moisture, releasing
      17ß-estradiol.

      The estradiol in estradiol vaginal tablet is chemically and biologically identical to the
      endogenous human estradiol and is therefore classified as a human estrogen.

      The purpose of this study is to demonstrate clinical endpoint bioequivalence of SPIL's
      Estradiol vaginal tablet, 10mcg estradiol to the reference listed drug (Vagifem®)which is
      approved and marketed in the US.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Estradiol vaginal tablet is indicated for use in the treatment of symptoms of atrophic
      vaginitis due to estrogen deficiency.

      This is a randomized, observer blind, parallel groups, active and placebo controlled study to
      test the clinical endpoint bioequivalence of test product (Estradiol vaginal tablet, 10mcg of
      Sun Pharmaceutical Industries Ltd. India) relative to reference (Vagifem®, Estradiol vaginal
      tablet, 10mcg estradiol of Novo Nordisk) in treatment of vulvar and vaginal atrophy.

      The patients will be administered with one tablet intravaginally daily for 14 days.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment
  </why_stopped>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vaginal pH</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms of vulvar and vaginal atrophy</measure>
    <time_frame>14 days</time_frame>
    <description>Each subject will specify identified most bothersome symptoms vaginal dryness, vaginal and/or vulvar irritation/ itching, dysuria, vaginal pain associated with sexual activity, vaginal bleeding associated with sexual activity) and self-evaluate the symptom on a pre-defined scale</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Vulvar Atrophy</condition>
  <condition>Vaginal Atrophy</condition>
  <arm_group>
    <arm_group_label>Estradiol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravaginal self-administration of study medication once daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference: Estradiol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravaginal self-administration of study medication once daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravaginal self-administration of study medication once daily for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol</intervention_name>
    <description>one tablet will be inserted daily for 14 days</description>
    <arm_group_label>Estradiol</arm_group_label>
    <arm_group_label>Reference: Estradiol</arm_group_label>
    <other_name>Vagifem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal woman

          -  At least one subject-self-assessed moderate to severe symptom of vulvar and vaginal
             atrophy

          -  ≤ 5% superficial cells on vaginal smear cytology

          -  Vaginal pH &gt; 5.0

        Exclusion Criteria:

          -  Consumption of estrogen alone or estrogen/progestin containing drug products.

          -  Allergy to estradiol or related products

          -  History of breast cancer and significant risk factors for endometrial cancer

          -  Abnormal genital bleeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Biniwale Clinic Pvt. Ltd,</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2012</study_first_submitted>
  <study_first_submitted_qc>December 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2012</study_first_posted>
  <last_update_submitted>May 19, 2015</last_update_submitted>
  <last_update_submitted_qc>May 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Estradiol</keyword>
  <keyword>Vulvar atrophy</keyword>
  <keyword>vaginal atrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

